 |
 |
E-MOVE reports from the 61st Annual Meeting of the American Academy of Neurology, held in Seattle, WA, April 25th - May 2nd, 2009. Poster and Session numbers refer to their listing in Neurology, 2009;72(suppl3) Botulinum toxin type B is safe and effective for sialorrhea in Parkinson's disease, according to this study. Fifty-four patients were randomized to placebo or BoNT-B at one of three doses-1500U, 2500U, or 3500U, with 250U injected into each submandibular gland, and the remaining dose divided and injected into each parotid gland, by anatomic guidance. Drooling Frequency and Severity Scale scores (on a 5-point scale) were determined by patient and investigator at baseline and post- injection weeks 1, 2, and 4, and 5-minute salivary flow rates were determined. At 4 weeks, DFSS scores had declined (improved) from baseline by approximately 1.2, 2.2, 3.4, and 3.5 points for each group, respectively (p=0.191, <0.0001, <0.0001 vs. placebo). Active treatment led to an approximately 50% decline in salivary flow compared to no change from placebo treatment, with a gradual return toward baseline flow over 12-16 weeks. Treatment-emergent adverse events were reported by 53% of patients receiving placebo and 56% of patients receiving active treatment. Dry mouth was reported more commonly by those on active treatment. "Anatomically guided intraglandular injections of BoNT-B for the treatment of troublesome sialorrhea in patients with PD appears to be well tolerated and efficacious," the authors conclude. Supported by Solstice Neurosciences Efficacy and Safety of botulinum toxin type B (Myobloc®) for the treatment of sialorrhea in Parkinson's disease E Salazar-Grueso, P Hogan, F Pagan, S Reinhard, E Pappert, W Birmingham P01.067 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn